XSTO
S2M
Market cap436kUSD
Oct 09, Last price
0.00SEK
1D
0.00%
1Q
-30.77%
IPO
-99.98%
Name
S2Medical AB (publ)
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
S2Medical AB (publ) focuses on the development, production, and commercialization of advanced wound care solutions, specifically targeting burns and chronic wounds. Their product range features INSTAQRETT, a sterile, disposable tool for mechanical debridement; EPIPROTECT SafeStop, designed to control bleeding; and Instagraft, a single-use medical device for treating complex and prolonged wounds. The company also supplies EPIPROTECT tissue replacement products and INSTABIND-branded bandages, which are known for being washable, waterproof, and self-adhesive. Furthermore, S2Medical distributes Silverlon dressings, which facilitate the delivery of silver ions to the wound. In addition to its product offerings, the company operates specialized wound healing centers known as S2Clinic. Founded in 2013, S2Medical is headquartered in Linköping, Sweden.
Key people
Petter Sivler
Chief Executive Officer · since 2013
Erika Tapani
Chief Financial Officer · since 2020
Marten Skog
Chief Operating Officer, Director
Director · since 2019
Independent Director · since 2018
Roland Frosing
Independent Director · since 2018
Amin Omrani
Independent Chairman of the Board · since 2019
Headquarters & legal address
Sunnorpsgatan 5
Linköping, E 582 73
SE
Linköping, E 582 73
SE
Address
Sunnorpsgatan 5
Linkoping, E 582 73
SE
Linkoping, E 582 73
SE
Previous name
S2Medical AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||